logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme Gets Complete Response Letter From FDA On Lemtrada Application

Genzyme, a Sanofi company (SNY,SNYNF.PK), said it has received a Complete Response Letter from the U.S. Food and Drug Administration or FDA for its supplemental Biologics License Application seeking approval of Lemtrada or alemtuzumab for the treatment of relapsing forms of multiple sclerosis. Alemtuzumab is a monoclonal antibody that selectively targets CD52, a protein abundant on T and B cells.

A Complete Response Letter informs companies that an application is not yet ready for approval. FDA has taken the position that Genzyme has not submitted evidence from adequate and well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects. Genzyme understands that the conclusion is related to the design of the completed Phase 3 active comparator studies of Lemtrada in relapsing-remitting MS patients. Moreover, FDA has taken the position that one or more additional active comparator trials of different design and execution are needed prior to the Lemtrada approval.

Genzyme strongly disagrees with the FDA's conclusions and intends to appeal the agency's decision.

Lemtrada is approved in the European Union, Canada, and Australia, and additional marketing applications for Lemtrada are under review by regulatory agencies worldwide. Sanofi does not expect that the CVR milestone of U.S. approval of Lemtrada by March 31, 2014 would be met.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Shares of Airbus Group SE were losing around 4 percent in the morning trading in Paris after the aerospace and defense major reported Thursday a sharp decline in its second-quarter profit with lower revenues. Further, the company maintained its guidance for the full year 2017. Micro-blogging site Twitter Inc.'s shares tumbled more than 9 percent in pre-market activity on Thursday after the company reported monthly active users' figure for the second quarter that was unchanged from previous quarter. Twitter also reported a loss for the second quarter that widened from last year on lower revenues. However, adjusted earnings and revenue beat analysts' expectations. Deutsche Bank AG on Thursday reported significantly higher profit in its second quarter with lower provision for credit losses and lower expenses. Meanwhile, the company said the level of profitability falls short of its longer term aspirations. Revenues declined with weak results in all segments. The shares of the German banking giant were declining around 4 percent in the morning trading.
comments powered by Disqus
Follow RTT